"Talk to your patients. If they’re high risk and they want more treatment, then you consider it. We don’t force niacin. It’s not mandated. I think that’s where we are at the moment. Maybe a year or two from now, we’ll have some better answers," he said.
Simultaneously with Dr. Boden’s detailed presentation of the AIM-HIGH results in a late-breaking-trials session at the AHA meeting, the study was published online (N. Engl. J. Med. 2011 Nov. 15 [doi:10.1056/NEJMoa1107579]).
The AIM-HIGH study was funded by the National Heart, Lung, and Blood Institute and an unrestricted grant from Abbott Laboratories. Dr. Boden disclosed having received consulting fees from the company. Dr. Barter and Dr. Brinton declared having no financial conflicts.